Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ascending multiple oral dose study of SEP-363856 in Japanese subjects with schizophrenia
jRCT2080223731Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ulotaront in schizophrenia, sponsored by Sumitomo Pharma. Primary endpoints: Safety and tolerability of SEP-363856 and Pharmacokinetics of SEP-363856. Started Nov 2017; status: completed.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2080223731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223731.